In a regulatory filing, the company stated, “On June 24, 2025, the board of directors of Roivant Sciences (ROIV) authorized a common share repurchase program allowing for repurchases of the company’s common shares in an aggregate amount of up to $500 million. This new authorization is in addition to the $1.5 billion common share repurchase program announced in April 2024, which had approximately $205 million of remaining capacity as of March 31, 2025 and has since been fully exhausted.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Optimistic Outlook for Roivant Sciences: Buy Rating Backed by Brepo’s Potential and Financial Opportunities
- Optimistic Outlook for Roivant Sciences Driven by Promising Brepocitinib Results in Phase 3 VALOR Study
- Roivant Sciences’ Growth Potential Highlighted by Upcoming Phase 3 VALOR Study for Brepocitinib
- JPMorgan positive on Roivant into dermatomyositis readout
- Roivant Sciences to hold an investor webinar